Physician profile
Daniel Jin Lee
NPI 1265461610
$3,255.14
in general payments reported to CMS, 2019-2025
14 companies · $435 in 2025
The $435 reported for 2025 was more than what 76% of Nuclear Medicine providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $483 · 2020: $1,681 · 2021: $157 · 2022: $180 · 2023: $113 · 2024: $207 · 2025: $435.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $754.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $754.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ge Healthcare | $2,082.42 | 2019-2025 | |
| Penumbra, INC. | $193.67 | 2025 | Indigo System, Ruby Coil |
| Progenics Pharmaceuticals, INC. | $169.64 | 2022-2025 | Pylarify |
| Boston Scientific Corporation | $162.28 | 2020-2022 | |
| Telix Pharmaceuticals | $151.28 | 2024 | Illuccix |
| Siemens Medical Solutions USA, INC. | $114.05 | 2021-2023 | Biograph Horizon-3r |
| Advanced Accelerator Applications | $110.00 | 2019 | |
| Astellas Pharma US INC | $100.85 | 2019 | |
| Canon Medical Systems USA, INC. | $39.77 | 2025 | Interventional Angiography System |
| Inari Medical, INC. | $31.55 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Dompe US, INC. | $29.73 | 2024 | Oxervate |
| Novartis Pharmaceuticals Corporation | $25.75 | 2024 | |
| Paratek Pharmaceuticals, INC. | $23.53 | 2023 | Nuzyra |
| Acacia Pharma INC | $20.62 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.